| Literature DB >> 33229651 |
Vardhaman P Kankariya1, Ankita B Dube1, Michael A Grentzelos2, George A Kontadakis3, Vasilios F Diakonis4, Myrsini Petrelli5, George D Kymionis5.
Abstract
The past two decades have witnessed an unprecedented evolution in the management of keratoconus that demands a holistic approach comprising of inhibiting the ectatic progression as well as visual rehabilitation. The advent of corneal cross-linking (CXL) in the late 1990s resulted in long-term stabilization of the ectatic cornea along with limited reduction in corneal steepening and regularization of corneal curvature. However, CXL as a standalone procedure does not suffice in rehabilitating the functional vision especially in patients who are unwilling or intolerant towards contact lenses. The concept of "CXL plus" was proposed which incorporates adjunctive use of refractive procedures with CXL in order to overcome the optical inefficiency due to corneal irregularity, decrease the irregular astigmatism, correct the residual refractive error and improve functional visual outcome in keratoconus. Several refractive procedures such as conductive keratoplasty (CK), photorefractive keratectomy (PRK), transepithelial phototherapeutic keratectomy (t-PTK), intrastromal corneal ring segments (ICRS) implantation, phakic intraocular lens (PIOL) implantation and multiple other techniques have been combined with CXL to optimize and enhance the CXL outcome. This review aimed to summarize the different protocols of CXL plus, provide guidelines for selection of the optimum CXL plus technique and aid in decision-making for the comprehensive management of cases with primary keratoconus in addition to discussing the future and scope for innovations in the existing treatment protocols.Entities:
Keywords: CXL Plus; corneal irregularity; functional vision; keratoconus; refractive
Mesh:
Substances:
Year: 2020 PMID: 33229651 PMCID: PMC7856931 DOI: 10.4103/ijo.IJO_1841_20
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Summary of Outcomes with Combined PRK and CXL
| Author | Study design | Surgical Procedure (Number of eyes) | Follow-up | Outcomes |
|---|---|---|---|---|
| Kanellopoulos and Binder[ | Case report | CXL followed by topo-guided PRK 12 months later (1) | 18 months | Significant clinical improvement and stability; no complications observed |
| Kymionis | Pilot study (Prospective) | Simultaneous topo-guided PRK followed by CXL (14) | 10.69±5.95 months (range: 3 to 16 months) | Significant improvement in UDVA, CDVA, SE, defocus and keratometry readings; no complications observed |
| Kanellopoulos[ | Retrospective, comparative study | Sequential CXL with delayed PRK and simultaneous topo-guided PRK followed by CXL (127 and 198, respectively) | 36±18 months (range: 24 to 68 months) | Simultaneous group performed better in all parameters (UDVA, CDVA, keratometry, SE, corneal haze); significant haze noted in 19 eyes (17 of sequential and 2 of simultaneous group) |
| Krueger and Kanellopoulos[ | Case series | Simultaneous topo-guided PRK and CXL (2) | 36 and 30 months | Reduction of spherocylindrical refraction and improvement in functional vision; no complications observed |
| Stojanovic | Case series | Topography-guided transepithelial custom ablation followed by CXL (7) | 12 months | Visual, refractive, and topographic improvement; no complications observed |
| Kymionis | Prospective case series | Simultaneous topo-guided PRK followed by CXL (31) | 19.53±3.97 months, (range: 12 to 25 months) | Significant improvement in UDVA, CDVA, SE and keratometry; no progression of keratoconus; 16 of 31 eyes showed posterior linear stromal haze |
| Tuwairqi and Sinjab[ | Prospective, non-randomized, non-controlled study | Simultaneous topography-guided PRK and CXL (22) | 12 months | Significant improvement in all study parameters (UDVA, CDVA, sphere, SE, manifest and topographic astigmatism, keratometry); no complications observed |
| Alessio | Prospective, non-randomized clinical trial | Simultaneous transepithelial topo-guided PRK and CXL versus CXL only (17 in each group) | 24 months | PRK-CXL provided better UDVA/CDVA and lower SE, spherical/cylindrical power and keratometric values than CXL; no complications observed |
| Kontadakis | Prospective, comparative case series | Simultaneous topo-guided PRK and CXL versus CXL only (60) | 39±11 months | Significant improvement in UDVA, CDVA, keratometry, SE and defocus equivalent with significant corneal flattening in PRK-CXL group; no complications observed |
| Iqbal | Prospective, multicentre, comparative, clinical | Standard CXL (group A) versus non-topo-guided PRK and accelerated CXL (group B) (58/67) | 24 months | Group B showed significant and early reduction in myopia and astigmatism, Group A showed similar effect on corneal flattening, sphere reduction and equivalent visual outcome at 24 months postoperatively; delayed epithelial healing in 9 eyes and corneal haze in 11 eyes resolved completely; one eye in group B developed stromal scarring |
| Kanellopoulos[ | Prospective | Simultaneous topo-Guided Partial-Refraction PRK and CXL (144) | 128±4 months (range: 120 to 146 months) | Significant and stable improvement in UDVA, CDVA and keratometry |
| Kanellopoulos and Asimellis[ | Case series | Simultaneous topo-guided PRK and high-fluence CXL (231) | 36 months | Visual (UDVA and CDVA) and topographic improvement; no complications observed |
| Kaiserman | Retrospective, case series | Epithelial PRK and accelerated CXL (20) | 822.5±336.7 days (range: 266 to 1,749 days) | Significant improvement in UDVA, CDVA and keratometry; no complications observed |
| Shetty | Prospective, case series | Combined same-day topography-guided custom ablation treatment (T-CAT) followed by accelerated CXL (2) | 6 months | Improvement in UDVA, CDVA and keratometry |
| Shetty | Prospective, comparative case series | Simultaneous topo-guided PRK followed by enhanced-intensity CXL (29) | 12 months | Improvement in visual and keratometric parameters |
| Fadlallah | Retrospective, non-randomized study | Non-topo-guided PRK and CXL (140) | 24 months | Significant improvement in UDVA, SE and mean cylinder; 4 eyes developed mild haze |
| Al-Amri[ | Prospective, interventional, non-randomized, non-controlled case series | Non-topo-guided PRK and CXL (60) | 68.20±4.71 months (range: 60-106 months) | Significant improvement in UDVA, CDVA, SE and keratometry, no serious complications observed, 4 eyes developed mild haze |
| Shaheen | Prospective uncontrolled interventional case series | CXL followed by WFG PRK 12 months later (34) | 12 months | Significant improvement in UDVA, CDVA, manifest sphere and cylinder as well as ocular HOAs |
| Gore | Prospective case series | Simultaneous transepithelial WFG PRK and accelerated CXL (47) | 24 months | Significant improvement in CDVA, keratometric parameters and coma; one eye lost ≥2 lines of CDVA |
| Abou Samra | Prospective | Simultaneous WFG PRK and accelerated CXL versus sequential WFG PRK 6 months after CXL (62) | 12 months | Significant improvement in visual, refractive, keratometric and aberrometric parameters with no significant difference between the 2 groups |
PRK=Photorefractive keratectomy; CXL=Corneal cross-linking; UDVA=Uncorrected distance visual acuity; CDVA=Corrected distance visual acuity; SE=Spherical equivalent; topo-guided=Topography guided; HOAs=Higher order aberrations; WFG=Wavefront guided
Summary of Outcomes with Combined t-PTK and CXL
| Author | Study design | Surgical Procedure (Number of eyes) | Follow-up | Outcomes |
|---|---|---|---|---|
| Kymionis | Case report | t-PTK followed by CXL (1) | 6 months | Visual and topographic improvement; no complications observed |
| Kymionis | Prospective, comparative, interventional case series | t-PTK (group 1) and mechanical epithelial debridement (group 2) during CXL (38) | 12 months | Significant improvement in UDVA, CDVA, steep keratometry and corneal astigmatism with t-PTK epithelial removal; no complications observed |
| Kymionis | Prospective case series | t-PTK followed by CXL (23) | 33.83±10.82 months (range: 24-56 months) | Significant improvement in UDVA, CDVA, keratometric values and corneal astigmatism; no complications observed |
| Kapasi | Retrospective, comparative | t-PTK during CXL (PTK group) and mechanical epithelial removal during CXL (mechanical group) (34) | 1 month | Significant improvement in SE and astigmatism in PTK group compared to mechanical group; no complications observed |
| Kapasi | Comparative | t-PTK during CXL (PTK group) and mechanical epithelial removal during CXL (mechanical group) (34) | 12 months | Significant improvement in CDVA and gain of CDVA lines in PTK group; no complications observed |
| Gaster | Retrospective, comparative study | manual epithelial debridement and ablation via PTK followed by CXL (339) | 24 months | Equivalent visual, refractive and keratometric outcomes between the two techniques |
| Grentzelos | Prospective, comparative, interventional case series | t-PTK (Cretan protocol group) and mechanical epithelial debridement (Dresden protocol group) during CXL (30) | 4 years | Significant and faster improvement in visual, refractive and keratometric values in Cretan protocol group; no complications observed |
| Chen | Retrospective case series | t-PTK followed by high intensity CXL (46) | 21.0±7.6 months (range: 10-43 months) | Significant improvement in CDVA and keratometric values and decrease in corneal HOAs; three eyes lost ≥2 lines of CDVA |
| Shetty | Case report | t-PTK with topography based ablation followed by accelerated CXL (3) | 3 months | Significant improvement in CDVA in 2/3 eyes, topography-based t-PTK technique ablated less stroma and achieved comparable outcomes |
| Sarac | Retrospective, comparative case series | mechanical (group 1) and t-PTK (group 2) based epithelial removal followed by accelerated CXL in pediatric population (40) | 36 months | UDVA, total RMS and keratometry improved significantly in both groups, however, improvement in CDVA, SE, HOA RMS and spherical aberration was significant in only group 2; corneal haze ratio was similar; no complications observed |
| Grentzelos | Prospective case series | t-PTK followed by simultaneous PRK and CXL (55) | 12 months | Significant improvement in UDVA, CDVA, SE and keratometry; no complications observed |
t-PTK=Transepithelial phototherapeutic keratectomy; CXL=Corneal cross-linking; UDVA=Uncorrected distance visual acuity; CDVA=Corrected distance visual acuity; SE=Spherical equivalent; HOAs=Higher order aberrations, RMS=Root mean square
Summary of Outcomes with Combined ICRS Implantation and CXL
| Author | Study design | Surgical procedures (Number of eyes) | Follow-up | Outcomes |
|---|---|---|---|---|
| Chan | Retrospective, comparative | Intacs alone/Intacs and CXL (12/13) | 102±39 days/97±38 days | Intacs with CXL showed significantly greater reduction in cylinder, topographic lower - upper ratio and steep and average keratometry, no complications observed |
| Renesto | Randomized clinical trial with 2 groups | Riboflavin only and ICRS 3 months later/CXL followed by ICRS 3 months later (19/20) | 24 months | No significant difference was identified between groups in UDVA, CDVA, SE, and spherical or cylindrical components; no complications observed |
| Legare | Retrospective, comparative | ICRS and same day CXL/ICRS alone (66) | 12 months | Significant improvement in UDVA, CDVA, sphere, cylinder, SE, keratometry and total HOAs in both the groups; no complications observed |
| Hersh | Prospective randomized clinical trial | ICRS with concurrent CXL/ICRS followed by CXL 3 months later (104/94) | 6 months | Substantial improvement in corneal topography with no significant difference between the sequential and concurrent groups, thicker segment size and single segment placement showed greater topographic improvement; No increase in the complication rate in comparison to each procedure alone; infectious keratitis in 2 eyes, inflammation around ICRS in 3 eyes (ICRS explanted in 2 eyes), glare symptoms in one eye (ICRS was explanted) |
| Henriquez | Prospective | CXL followed by Ferrara ICRS 6 months later (9) | 6 months | Significant visual improvement, reductions in SE and keratometry readings; no complications observed |
| El-Raggal[ | Prospective, Comparative | KeraRing insertion followed by CXL with a 6-month interval/2 step same day procedure (9/7) | 12 months | No significant differences in UDVA, CDVA, refractive error; however keratometric values showed greater reduction in the same day group; no complications observed |
| Saelens | Case series | Same-day Ferrara ICRS implantation and CXL (7) | 12 months | Significant improvement in SE and keratometry; inferior ring had to be removed in 1 patient because of implant migration |
| Ertan | Case series | ICRS followed by transepithelial CXL, 3.98 month interval (25) | 3 months | Additional improvement in UDVA, CDVA, sphere, cylinder and keratometry; no complications observed |
| El Awady | Prospective | KeraRing implantation followed by CXL at least 3 months later (21) | 5.67±1.89 months | All outcome measurements (UDVA, CDVA, SE, cylinder, and keratometry readings) were improved after KeraRing implantation and showed further improvement after CXL; no complications observed |
| Sharma | Prospective randomized | CXL alone/CXL combined with simultaneous ICRS implantation (20/18) | 12 months | CXL with ICRS yielded additional improvement in UDVA with significant reduction in cylinder and SE; no complications observed |
| Yeung | Retrospective comparative case series | Single or paired ICRS implantation with CXL (85) | 12 months | Outcomes were equivalent with single and paired implantation; no complications observed |
| Saleem | Retrospective, multicentre clinical | Paired KeraRing implantation with same session epithelium-on accelerated CXL (43) | 36 months | All outcome measurements (UDVA, CDVA, cylinder and keratometry readings) significantly improved; significant reduction in corneal thickness at the thinnest location was noted; 6 eyes showed progression who underwent standard CXL; 1 eye had exposure of ICRS but was stable after a repeat procedure 3 months later |
| Greenstein | Prospective, randomized clinical trial | Same session Intacs and CXL/sequential, Intacs followed by CXL 3 months later (158) | 6 months | Total anterior corneal HOA including vertical and horizontal coma significantly improved, spherical anterior corneal HOAs increased postoperatively with no change in trefoil |
| Nicula | Retrospective, comparative | KeraRing implantation followed by CXL 6 months later (group 1)/CXL followed by KeraRing implantation 6 months later (group 2) (41/30) | 12 months | Group 1 showed more significant improvement in SE, keratometry and cylinder compared to group 2; no complications observed |
| Coskunseven | Prospective, comparative, randomized | CXL followed by ICRS (group 1)/ICRS followed by CXL (group 2); mean interval: 7±2 months (48) | 13±1 months | Group 2 showed more improvement in CDVA, SE and mean keratometry than group 1; 8 eyes had slight corneal edema with stromal opacities, which disappeared within 3 months |
| El-Raggal[ | Comparative case series | Femtosecond-mediated channel creation using 1.5, 1.6, and 1.7 mJ power setting for ICRS insertion 6 months after CXL (15) | 6 months | Although channel for ICRS can be created after CXL by modifying the femtosecond laser power, channel dissection and ICRS implantation should be performed before or concurrent with CXL; corneal haze in all eyes resolved within 6 weeks |
| Kilic | Case series | Same-day combined ICRS and transepithelial CXL procedure, with 20% alcohol application and riboflavin injection into the corneal channel (131) | 7.07±4.66 months (range: 1 to 25 months) | Refractive and keratometric measurements improved in all cases; no complications observed |
| Alió | Retrospective, comparative, nonrandomized | ICRS followed by CXL (3 to 12 months later) either with epithelial debridement (classic group) or intrastromal pocket for riboflavin delivery (pocket group) (16/11) | 12 months | No statistically significant differences between the 2 groups in any of the parameters measured (UDVA, CDVA, sphere, cylinder, and keratometry values, corneal aberrations, and corneal pachymetry); significant corneal haze in all cases which resolved over time |
ICRS=Intrastromal corneal ring segments; CXL=Corneal cross-linking; CDVA=Corrected distance visual acuity; SE=Spherical equivalent; UDVA=Uncorrected distance visual acuity; HOAs=Higher order aberrations. The Intacs and Intacs SK are manufactured by Addition Technology, Lombard, IL. The Ferrara ICRS is manufactured by Ferrara Ophthalmics Ltda, Belo Horizonte, Brazil. The KeraRing is manufactured by Mediphacos, Belo Horizonte, Brazil
Summary of Outcomes with Combined CXL and PIOL Implantation
| Author | Study Design | Type of PIOL (Number of Eyes) | Interval between CXL and PIOL (Duration of follow-up) | Outcomes |
|---|---|---|---|---|
| Kymionis | Case Report | Posterior chamber: Toric Visian ICL (1) | 12 months (3 months) | Improvement in UDVA and CDVA; no complications observed |
| Izquierdo | Prospective | Iris claw: Artiflex (11) | 6 months (12 months) | Significant visual and refractive improvement with very low residual refractive error; no complications observed |
| Güell | Case series | Toric iris-fixated: Artiflex/Artisan (17) | 3.9±0.7 months; range: 3.1 to 5.5 months (36.9 months±15.0; range: 14 to 58 months) | Significant visual and refractive improvement, 94% eyes achieved UDVA of 20/40 or better and none of the eyes lost lines of CDVA; no complications observed |
| Fadlallah | Retrospective | Posterior chamber: Toric Visian ICL (16) | 6 months (6 months) | Significant visual and refractive improvement; no complications observed |
| Kurian | Prospective, Case series | Posterior chamber: Visian ICL (5) | 11.4±7.7 months (6 months) | Significant visual and refractive improvement; 2 eyes required adjunct ICRS implantation with CXL |
| Antonios | Retrospective | Posterior chamber: Toric Visian ICL (30) | 6 months (2 years) | Significant visual and refractive improvement; no complications observed |
| Shafik | Prospective, Interventional Case series | Posterior chamber: Toric Visian ICL (16) | 12 months (3 years) | Significant visual and refractive improvement; no complications observed |
CXL=Corneal cross-linking; PIOL=Phakic intraocular lens; ICL=Implantable collamer lens; UDVA=Uncorrected distance visual acuity; CDVA=Corrected distance visual acuity; ICRS=Intrastromal corneal ring segments. The Visian ICL is manufactured by STAAR Surgical, Monrovia, CA. The Artiflex and Artisan are manufactured by Ophtec BV, Groningen, The Netherlands
Summary of Outcomes with Combinations of Multiple Techniques and CXL
| Author | Study Design | Combined procedures (number of Eyes) | Order of the procedures (Duration of follow-up) | Outcomes |
|---|---|---|---|---|
| Kremer | Case series | ICRS, PRK, and CXL (45) | ICRS implantation followed by (6 months later) simultaneous wavefront-guided PRK and CXL (12 months) | Significant improvement in UDVA, CDVA, and keratometry values; no patient lost any line of CDVA; no ECD changes; Epithelial hyperplasia in 4 of 45 eyes |
| Coskunseven | Prospective | ICRS, CXL and PRK (16) | ICRS implantation followed by CXL followed by transepithelial topography-guided PRK with an interval of 6 months between each procedure (6 months) | UDVA, CDVA, SE, and keratometry values showed significant improvement; no eye lost any line of CDVA; no complications observed |
| Dirani | Retrospective | ICRS, CXL and PRK (17) | ICRS implantation followed by CXL with a 4-week interval followed by non-topography-guided PRK 6 months later (6 months) | UDVA, CDVA, SE, and keratometry values showed significant improvement; no complications observed |
| Al-Tuwairqi | Prospective | ICRS, CXL and PRK (41) | ICRS implantation followed by (6 months later) simultaneous topography-guided PRK and CXL (12 months) | Significant improvement in UDVA, SE and keratometry values, 85% of eyes maintained or gained multiple lines of CDVA; no complications observed |
| Lee | Retrospective | ICRS, PRK, and CXL (23) | ICRS implantation followed by combined corneal WFG-PRK (transepithelial) and high-fluence accelerated CXL 1 month later (6 months) | Significant improvement in UDVA, CDVA, SE, keratometry values and HOAs; no complications observed |
| Koh | Prospective | ICRS, PRK, and CXL (30) | ICRS implantation followed by (3 months later) simultaneous wavefront-guided PRK and CXL (12 months) | UDVA, CDVA, SE, and keratometry values improved with reduction in HOAs; no complications observed |
| Assaf | Prospective non-randomized | CXL, PRK, PIOL (22) | Topography-guided PRK followed by same day CXL (Athens protocol), followed by iris claw or angle-supported PIOL implantation 2-4 months later (6 months) | Significant improvement in CDVA, SE and keratometry values; no complications observed |
| Coskunseven | Case series | ICRS, CXL and PIOL (14) | ICRS implantation followed by CXL (>6 months) and then toric PIOL implantation (>6 months) (12 months) | Significant improvement in UDVA and CDVA in keratoconic eyes with high refractive error; no complications observed |
| Dirani | Retrospective | ICRS, CXL and PIOL (11) | ICRS implantation followed by CXL (4-week interval) and then toric PIOL implantation 6 months later (12 months) | Significant improvement in UDVA, CDVA, SE and keratometry; no complications observed |
| Abdelmassih | Consecutive case series | ICRS, CXL and PIOL (16) | ICRS implantation followed by CXL (4-week interval) and then toric PIOL implantation 6 months later (24 months) | Significant improvement in UDVA, CDVA, SE and keratometry; no complications observed |
| Yeung | Retrospective case series | t-PTK, ICRS and CXL (16) | Same-day t-PTK followed by single ICRS implantation and CXL (6.9±4.6 months) | Significant improvement in UDVA, CDVA and mean and steep keratometry values; no complications observed |
| Rocha | Prospective case series | t-PTK, ICRS and CXL (55) | ICRS implantation, followed by CXL and PTK (6 months) | Significant improvement in UDVA, CDVA sphere and cylinder; no complications observed |
| Coskunseven | Retrospective interventional case series | ICRS, CXL, PIOL, PRK (11) | ICRS implantation, followed by CXL followed by PIOL followed by topography-guided PRK with interval of 6 months between each procedure (12 months) | Significant improvement in UDVA, CDVA, SE and astigmatism; no complications observed |
CXL=Corneal cross-linking; ICRS=Intrastromal corneal ring segments; PRK=Photorefractive keratectomy; UDVA=Uncorrected distance visual acuity; CDVA=Corrected distance visual acuity; PIOL=Phakic intraocular lens; SE=Spherical equivalent; ECD=Endothelial cell density; t-PTK=Transepithelial phototherapeutic keratectomy; HOAs=Higher order aberrations, WFG=Wavefront-guided
Summary of Outcomes with LASIK Xtra, SMILE Xtra and PRK Xtra
| Author | Study Design | Surgical procedure (Number of Eyes) | Follow-up | Outcomes |
|---|---|---|---|---|
| Tomita | Contralateral eye, comparative case series | LASIK in one eye and LASIK Xtra in contralateral, non-dominant eye (24) | 12 months | No significant differences in UDVA, CDVA, MRSE, ECD, CH and CRF were found between the 2 procedures |
| Wu | Prospective controlled clinical trial | LASIK Xtra versus LASIK (96) | 6 months | No statistically significant differences in UDVA, CDVA, MRSE, keratometry, pachymetry and ECD; 2 eyes lost one or more lines in the LASIK-Xtra group |
| Low | Retrospective | LASIK Xtra versus LASIK (100) | 5.7 months (range: 1.5-13.3 months) | No significant difference in UDVA and efficacy and safety indices between the 2 groups |
| Kohnen | Prospective, randomized, fellow-eye controlled clinical trial | LASIK Xtra versus LASIK (52) | 12 months | No statistically significant differences in UDVA and MRSE between the 2 procedures |
| Seiler | Prospective, comparative study | LASIK Xtra versus LASIK (152) | 12 months | One month postoperatively, 5 eyes in LASIK Xtra group lost 1 line of CDVA compared with 1 eye in LASIK only group; refractive improvement was similar |
| Ganesh | Prospective | SMILE Xtra (40) | 12 months±28.12 days | No complications like haze, keratitis, ectasia or regression were observed; no eye lost lines of CDVA |
| Ng | Prospective, comparative interventional | SMILE Xtra/SMILE (21/32) | 6 months | No eye lost≥1 line of CDVA with good safety and efficacy indices in SMILE Xtra |
| Osman | Retrospective, comparative interventional | SMILE Xtra/SMILE (30/30) | 24 months | Significantly higher UDVA, CDVA, MRSE and CRF in SMILE Xtra group |
| Graue-Hernandez | Prospective, interventional, case series | SMILE Xtra in forme-fruste keratoconus (15) | 24 months | No intraoperative or postoperative complications observed |
| Sachdev | Interventional comparative case series | PRK Xtra/PRK (109/118) | 12 months | No iatrogenic ectasia or hyperopic shift noted in the PRK Xtra group; no significant difference in CDVA or incidence of haze |
| Ohana | Retrospective cohort | PRK Xtra (98) | 12 months | Refractive results less accurate than the published data for PRK-only procedure, No corneal ectasia noted, one eye lost 3 CDVA lines and 2 eyes lost 2 CDVA lines due to significant corneal haze |
LASIK=Laser in situ keratomileusis; SMILE=Small incision lenticule extraction; PRK=Photorefractive keratectomy; UDVA=Uncorrected distance visual acuity; CDVA=Corrected distance visual acuity; MRSE=Manifest refraction spherical equivalent; ECD=Endothelial cell density; CH=Corneal hysteresis; CRF=Corneal resistance factor
Figure 1Proposed algorithm to aid in decision-making for the comprehensive management of keratoconus. After diagnosing the disease, the treatment is planned after taking into consideration the stage of keratoconus, disease stability or progression, functional vision, preoperative corneal irregularity and astigmatism, corneal thickness and patient's willingness or tolerance towards contact lenses. VA = Visual acuity; RGP-CL = Rigid gas-permeable contact lens; DALK = Deep anterior lamellar keratoplasty; PKP = Penetrating keratoplasty; CXL = Corneal cross-linking; t-PTK = Transepithelial phototherapeutic keratectomy; PRK = Photorefractive keratectomy; ICRS = Intrastromal corneal ring segments; PIOL = Phakic intraocular lens; CT = Corneal thickness